Last updated: April 25, 2026
Taro Pharmaceuticals U.S.A., Inc. v. Perrigo UK FINCO Limited Partnership (1:15-cv-00859): Litigation Status, Claims, and Patent-Validity Posture
What is the case and where does it sit procedurally?
Caption: Taro Pharmaceuticals U.S.A., Inc. v. Perrigo UK FINCO Limited Partnership
Court / Docket: U.S. District Court (case no. 1:15-cv-00859)
Parties: Taro Pharmaceuticals U.S.A., Inc. (plaintiff) vs. Perrigo UK FINCO Limited Partnership (defendant)
Proceeding type (as reflected in public dockets and standard filing patterns): The matter is treated as a U.S. patent dispute arising from a generic entry pathway, with claims framed around infringement of specific Orange Book-listed patents and validity/unenforceability contentions typically paired to the asserted patent(s).
Result posture: A complete litigation disposition (claim-by-claim outcome, judgment date, injunction/damages rulings) is not determinable from the information provided in the prompt.
What patents were asserted and what was the claim scope?
The prompt does not include the asserted patent numbers, the Orange Book reference listed, the specific infringement theory (e.g., ANDA product, method claims), or whether the case proceeds under the Hatch-Waxman framework via § 271(e)(2) for an ANDA filing.
Without the asserted patent list and the operative complaint or claim charts, a complete claim-scope analysis cannot be produced.
What does the litigation tell investors about Perrigo’s patent-escape chances?
Investor-relevant read-throughs in Hatch-Waxman timing depend on three elements:
1) which patents were asserted,
2) whether the court reached validity (or only non-infringement), and
3) whether the case ended by settlement, summary judgment, or trial verdict.
The prompt provides only the case caption and docket number. It does not provide the court’s holdings, claim-construction rulings, or the final judgment record. A non-speculative assessment of Perrigo’s “patent-escape chances” would require the specific claim outcomes.
What are the common validity arguments in these disputes, and where would this case fit?
Typical validity challenges in Hatch-Waxman patent litigation include:
- § 102 novelty (single reference anticipation)
- § 103 obviousness (combination of references)
- § 112 (written description, enablement, indefiniteness)
- nonstatutory obviousness-type double patenting (when applicable)
This case’s actual validity posture cannot be mapped to those categories without the operative invalidity contentions and the court’s rulings.
How should product and market impact be modeled for Taro vs. Perrigo?
Modeling impact in 180-day exclusivity and generic launch timing requires:
- the asserted patent expiration dates and any terminal disclaimers,
- the outcome of any preliminary injunction requests,
- whether the case triggered any exclusivity settlement or FDA litigation stay changes, and
- whether the court’s outcome resulted in an injunction against launch or a legal determination of non-infringement.
None of those inputs are present in the prompt. A market-impact model would be incomplete.
What procedural milestones matter for diligence (and which are missing here)?
For diligence and underwriting, the key milestones are:
- service and initial responsive pleadings
- Markman claim construction timeline (if any)
- motions to dismiss / venue / pleading sufficiency
- summary judgment schedule
- bench trial or jury trial (if any)
- final judgment and appellate posture
- settlement orders or stipulated dismissals
Because the prompt does not provide the docket event list (dates and disposition entries), a precise milestones table cannot be produced.
Key Takeaways
- The prompt identifies the dispute and docket number (1:15-cv-00859) but does not provide the asserted patent list, operative claims, or the court’s rulings required to produce a litigation-grade infringement and validity analysis.
- A complete litigation summary (outcome, reasoning, and market implications) cannot be generated from the information supplied.
FAQs
1) What court and docket number is this case in?
U.S. District Court; docket 1:15-cv-00859.
2) Who are the parties?
Taro Pharmaceuticals U.S.A., Inc. (plaintiff) and Perrigo UK FINCO Limited Partnership (defendant).
3) Is this an ANDA-type Hatch-Waxman dispute?
The prompt does not state the filing framework or the FDA-related posture.
4) What patents were asserted?
No asserted patent numbers are included in the prompt.
5) What was the final case outcome?
No judgment or dismissal details are included in the prompt.
References
[1] Taro Pharmaceuticals U.S.A., Inc. v. Perrigo UK FINCO Limited Partnership, No. 1:15-cv-00859 (U.S. District Court).
